Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Dynavax Presents Topline Data From Part 1 Of Phase 1/2 Trial For Shingles Vaccine Candidate At IDWeek 2025; Announces Initiation Of Part 2 Of Trial

Author: Benzinga Newsdesk | October 21, 2025 03:03pm

Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profile
Newly presented data outline robust polyfunctional CD4+ T-cell responses in Z-1018 arms
- Company initiates Part 2 of Phase 1/2 head-to-head versus Shingrix in adults 70 years and older

Posted In: DVAX